Evidence map›Paper›PMID 40260530›Full record

ArticleRenal failure2025

Circ-0069561 as a novel diagnostic biomarker for progression of diabetic kidney disease.

Chaoyi Chen, Xinran Liu, Sai Zhu, Yukai Wang, Yu Ma, Ziyun Hu, Yonggui Wu, Ling Jiang

Abstract read
In one paragraph

Article in Renal failure, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
  4. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Chaoyi ChenDepartment of Nephropathy, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Xinran LiuDepartment of Nephropathy, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Sai ZhuDepartment of Nephropathy, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Yukai WangDepartment of Nephropathy, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Yu MaDepartment of Nephropathy, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Ziyun HuDepartment of Nephropathy, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Yonggui WuDepartment of Nephropathy, The First Affiliated Hospital of Anhui Medical University, Hefei, China.
Ling JiangDepartment of Nephropathy, The First Affiliated Hospital of Anhui Medical University, Hefei, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundCircular RNAs (circRNAs) are non-coding RNAs that are key regulators of the initiation and progression of various human diseases. However, the role of circRNAs in diabetic kidney disease (DKD) remains unknown.

methodsWhole high-throughput RNA sequencing (RNA-seq) was performed on kidney tissues from clinical DKD patients and controls. Circ-0069561 with significantly up-regulated expression level was selected by real-time PCR (RT-PCR) analysis. RT-PCR and fluorescent

resultsThe top 10 up-regulated circular RNAs were selected by RT-PCR validation, and the results demonstrated a significant elevation in the expression level of circ-0069561. The RT-PCR and FISH results demonstrated that the expression of circ-0069561 was elevated in renal tissues of type 2 diabetic mice and DKD patients, with a predominant localization in glomerulus. The ROC curves showed that circ-0069561 had a good diagnostic value in massive proteinuria (area under the curve = 0.889). Kaplan-Meier analysis showed that high expression of circ-0069561 was associated with an increased risk of primary endpoints. The circRNA-miRNA-mRNA network indicated that ferroptosis might be involved in the pathogenesis of DKD.

conclusionCirc-0069561 has the potential to be an ideal biomarker and therapeutic target for DKD progression.

Indexed as

Diabetes Mellitus, Type 2Diabetic NephropathiesRNA, CircularAnimalsBiomarkersDiabetes Mellitus, ExperimentalDisease ProgressionFemaleHumansMaleMiceMicroRNAsMiddle AgedPodocytesUp-RegulationBiomarkersMicroRNAsRNA, CircularCircRNAsDiabetic kidney diseaseferroptosistranscriptome sequencing

Identifiers

PMID40260530
PMCPMC12016256

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.